Characterization of kinases involved in the phosphorylation of aggregated α-synuclein

Journal of Neuroscience Research

Volumn 89, Issue 2, 2011, Pages 231-247

  Waxman, Elisa A ^a   Giasson, Benoit I ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

synuclein; Aggregation; Parkinson's disease; Phosphorylation; Polo like kinase

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; ALPHA SYNUCLEIN; CASEIN KINASE II; POLO LIKE KINASE 1; POLO LIKE KINASE 2;

ARTICLE; CONTROLLED STUDY; ENZYME ANALYSIS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION;

ALPHA-SYNUCLEIN; BLOTTING, WESTERN; CELL LINE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INCLUSION BODIES; PHOSPHORYLATION; PROTEIN KINASES;

EID: 78650203006     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22537     Document Type: Article

References (56)

1. Ahn KJ, Paik SR, Chung KC, Kim J. 2006. Amino acid sequence motifs and mechanistic features of the membrane translocation of alpha-synuclein. J Neurochem 97: 265-279.
2. Aiyar N, Disa J, Dang K, Pronin AN, Benovic JL, Nambi P. 2000. Involvement of G protein-coupled receptor kinase-6 in desensitization of CGRP receptors. Eur J Pharmacol 403: 1-7.
3. Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, Diep L, Keim PS, Shen X, Chataway T, Schlossmacher MG, Seubert P, Schenk D, Sinha S, Gai WP, Chilcote TJ. 2006. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281: 29739-29752.
4. Azeredo da Silveira SZ, Schneider BL, Cifuentes-Diaz C, Sage D, bbas-Terki T, Iwatsubo T, Unser M, Aebischer P. 2009. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Hum Mol Genet 18: 872-887.
5. Chau KY, Ching HL, Schapira AH, Cooper JM. 2009. Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson's disease pathogenesis. J Neurochem 110: 1005-1013.
6. Chen L, Feany MB. 2005. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 8: 657-663.
7. Damier P, Hirsch EC, Agid Y, Graybiel AM. 1999. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122: 1437-1448.
8. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ. 2009. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 106: 13010-13015.
9. Duda JE, Giasson BI, Gur TL, Montine TJ, Robertson D, Biaggioni I, Hurtig HI, Stern MB, Gollomp SM, Grossman M, Lee VMY, Trojanowski JQ. 2000. Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy. J Neuropathol Exp Neurol 59: 830-841.
10. Duda JE, Giasson BI, Mabon ME, Lee VMY, Trojanoswki JQ. 2002. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol 52: 205-210.
11. Forman MS, Lee VM, Trojanowski JQ. 2005. Nosology of Parkinson's disease: looking for the way out of a quackmire. Neuron 47: 479-482.
12. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T. 2002. α-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4: 160-164.
13. Gelb DJ, Oliver E, Gilman S. 1999. Diagnostic criteria for Parkinson disease. Arch Neurol 56: 33-39.
14. Giasson BI, Jakes R, Goedert M, Duda JE, Leight S, Trojanowski JQ, Lee VMY. 2000. A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J Neurosci Res 59: 528-533.
15. Giasson BI, Murray IVJ, Trojanowski JQ, Lee VMY. 2001. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem 276: 2380-2386.
16. Goedert M. 2001. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2: 492-501.
17. Gorbatyuk OS, Li S, Sullivan LF, Chen W, Kondrikova G, Manfredsson FP, Mandel RJ, Muzyczka N. 2008. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad Sci U S A 105: 763-768.
18. Greenbaum EA, Graves CL, Mishizen-Eberz AJ, Lupoli MA, Lynch DR, Englander SW, Axelsen PH, Giasson BI. 2005. The E46K mutation in alpha-synuclein increases amyloid fibril formation. J Biol Chem 280: 7800-7807.
19. Harris PL, Zhu X, Pamies C, Rottkamp CA, Ghanbari HA, McShea A, Feng Y, Ferris DK, Smith MA. 2000. Neuronal polo-like kinase in Alzheimer disease indicates cell cycle changes. Neurobiol Aging 21: 837-841.
20. Inglis KJ, Chereau D, Brigham EF, Chiou SS, Schobel S, Frigon NL, Yu M, Caccavello RJ, Nelson S, Motter R, Wright S, Chian D, Santiago P, Soriano F, Ramos C, Powell K, Goldstein JM, Babcock M, Yednock T, Bard F, Basi GS, Sham H, Chilcote TJ, McConlogue L, Griswold-Prenner I, Anderson JP. 2009. Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J Biol Chem 284: 2598-2602.
21. Johnson EF, Stewart KD, Woods KW, Giranda VL, Luo Y. 2007. Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity. Biochemistry 46: 9551-9563.
22. Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen H, Spooren W, Fuss B, Mallon B, Macklin WB, Fujiwara H, Hasegawa M, Iwatsubo T, Kretzschmar HA, Haass C. 2002. Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep 3: 583-588.
23. 2+- and integrin-binding protein and are regulated dynamically with synaptic plasticity. EMBO J 18: 5528-5539.
24. Kragh CL, Lund LB, Febbraro F, Hansen HD, Gai WP, El-Agnaf O, Richter-Landsberg C, Jensen PH. 2009. α-Synuclein aggregation and ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J Biol Chem 284: 10211-10222.
25. Lee HJ, Suk JE, Bae EJ, Lee JH, Paik SR, Lee SJ. 2008. Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int J Biochem Cell Biol 40: 1835-1849.
26. Lee VM, Trojanowski JQ. 2006. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron 52: 33-38.
27. Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ. 1999. Dementia with Lewy bodies. Neurology 52: 893.
28. Liu J, Zhang JP, Shi M, Quinn T, Bradner J, Beyer R, Chen S, Zhang J. 2009. Rab11a and HSP90 regulate recycling of extracellular alpha-synuclein. J Neurosci 29: 1480-1485.
29. Lowery DM, Lim D, Yaffe MB. 2005. Structure and function of Polo-like kinases. Oncogene 24: 248-259.
30. Mazzulli JR, Mishizen AJ, Giasson BI, Lynch DR, Thomas SA, Nakashima A, Nagatsu T, Ota A, Ischiropoulos H. 2006. Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J Neurosci 26: 10068-10078.
31. Mbefo MK, Paleologou KE, Boucharaba A, Oueslati A, Schell H, Fournier M, Olschewski D, Yin G, Zweckstetter M, Masliah E, Kahle PJ, Hirling H, Lashuel HA. 2010. Phosphorylation of synucleins by members of the Polo-like kinase family. J Biol Chem 285: 2807-2822.
32. Neumann M, Kahle PJ, Giasson BI, Ozmen L, Borroni E, Spooren W, Muller V, Odoy S, Fujiwara H, Hasegawa M, Iwatsubo T, Trojanowski JQ, Kretzschmar HA, Haass C. 2002. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest 110: 1429-1439.
33. Nishie M, Mori F, Fujiwara H, Hasegawa M, Yoshimoto M, Iwatsubo T, Takahashi H, Wakabayashi K. 2004. Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. Acta Neuropathol 107: 292-298.
34. Okochi M, Walter J, Koyama A, Nakajo S, Baba M, Iwatsubo T, Meijer L, Kahle PJ, Haass C. 2000. Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J Biol Chem 275: 390-397.
35. Pagano MA, Andrzejewska M, Ruzzene M, Sarno S, Cesaro L, Bain J, Elliott M, Meggio F, Kazimierczuk Z, Pinna LA. 2004a. Optimization of protein kinase CK2 inhibitors derived from 4, 5, 6, 7-tetrabromobenzimidazole. J Med Chem 47: 6239-6247.
36. Pagano MA, Meggio F, Ruzzene M, Andrzejewska M, Kazimierczuk Z, Pinna LA. 2004b. 2-Dimethylamino-4, 5, 6, 7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. Biochem Biophys Res Commun 321: 1040-1044.
37. Pagano MA, Poletto G, DiMaira G, Cozza G, Ruzzene M, Sarno S, Bain J, Elliott M, Moro S, Zagotto G, Meggio F, Pinna LA. 2007. Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem 8: 129-139.
38. Pak DTS, Sheng M. 2003. Targeted protein degradation and synapse remodeling by an inducible protein kinase. Science 302: 1368-1373.
39. Pakkenberg B, Moller A, Gundersen HJ, Mouritzen DA, Pakkenberg H. 1991. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry 54: 30-33.
40. Paleologou KE, Schmid AW, Rospigliosi CC, Kim HY, Lamberto GR, Fredenburg RA, Lansbury PTJr, Fernandez CO, Eliezer D, Zweckstetter M, Lashuel HA. 2008. Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J Biol Chem 283: 16895-16905.
41. Paleologou KE, Oueslati A, Shakked G, Rospigliosi CC, Kim HY, Lamberto GR, Fernandez CO, Schmid A, Chegini F, Gai WP, Chiappe D, Moniatte M, Schneider BL, Aebischer P, Eliezer D, Zweckstetter M, Masliah E, Lashuel HA. 2010. Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J Neurosci 30: 3184-3198.
42. Paxinou E, Chen Q, Weisse M, Giasson BI, Norris EH, Rueter SM, Trojanowski JQ, Lee VMY, Ischiropoulos H. 2001. Induction of alpha-synuclein aggregation by intracellular nitrative insult. J Neurosci 21: 8053-8061.
43. Pronin AN, Morris AJ, Surguchov A, Benovic JL. 2000. Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J Biol Chem 275: 26515-26522.
44. Simuni T, Hurtig HI. 2000. Parkinson's disease: the clinical picture. In: Clark CM, Trojanoswki JQ, editors. Neurodegenerative dementias. New York: McGraw-Hill. p 193-203.
45. Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M. 1997. Alpha-synuclein in Lewy bodies. Nature 388: 839-840.
46. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. 1998. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 251: 205-208.
47. Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M, Gnrtler U, Garin-Chesa P, Lieb S, Quant J, Grauert M, Adolf GR, Kraut N, Peters JM, Rettig WJ. 2007. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 17: 316-322.
48. Sugeno N, Takeda A, Hasegawa T, Kobayashi M, Kikuchi A, Mori F, Wakabayashi K, Itoyama Y. 2008. Serine 129 phosphorylation of alpha-synuclein induces unfolded protein response-mediated cell death. J Biol Chem 283: 23179-23188.
49. Tategu M, Nakagawa H, Sasaki K, Yamauchi R, Sekimachi S, Suita Y, Watanabe N, Yoshid K. 2008. Transcriptional regulation of human polo-like kinases and early mitotic inhibitor. J Genet Genomics 35: 215-224.
50. Tu PH, Galvin JE, Baba M, Giasson B, Tomita T, Leight S, Nakajo S, Iwatsubo T, Trojanowski JQ, Lee VMY. 1998. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol 44: 415-422.
51. von Bohlen Und HO. 2004. Synucleins and their relationship to Parkinson's disease. Cell Tissue Res 318: 163-174.
52. Waxman EA, Giasson BI. 2008. Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J Neuropathol Exp Neurol 67: 402-416.
53. Waxman EA, Giasson BI. 2010. A novel, high-efficiency cellular model of fibrillar alpha-synuclein inclusions and the examination of mutations that inhibit amyloid formation. J Neurochem 113: 374-388.
54. Waxman EA, Duda JE, Giasson BI. 2008. Characterization of antibodies that selectively detect alpha-synuclein in pathological inclusions. Acta Neuropathol 116: 37-46.
55. Waxman EA, Covy JP, Bukh I, Li X, Dawson TM, Giasson BI. 2009. Leucine-rich repeat kinase 2 expression leads to aggresome formation that is not associated with alpha-synuclein inclusions. J Neuropathol Exp Neurol 68: 785-796.
56. Winkles JA, Alberts GF. 2005. Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues. Oncogene 24: 260-266.